Avecho Biotechnology CEO Paul Gavin talked with Proactive at the ASX Small and Mid-Cap Conference about its Phase 3 study into insomnia and its proprietary drug delivery system. Avecho Biotechnology Limited develops and commercialises innovative Human and Animal Health products using its proprietary drug delivery system called Tocopheryl Phosphate Mixture (TPM®). TPM is derived from Vitamin E using unique, proprietary and patented processes and is proven to enhance the solubility and oral, dermal and transdermal absorption of drugs and nutrients. Avecho’s lead asset is a proprietary cannabidiol (“CBD”) TPM soft-gel capsule demonstrated to increase CBD absorption. The CBD soft-gel capsule is currently undergoing Phase III clinical development for the treatment of insomnia. #AvechoBiotechnology #ProactiveInvestors #PaulGavin #DrugDelivery #PharmaceuticalDevelopment